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ABSTRACT
Introduction: PIAS1 and PIAS2 (protein inhibitor of activated
STAT 1,2) play key roles in the pathogenesis of autoimmune
and inflammatory diseases. This study aims to evaluate the
gene expression of these factors in multiple sclerosis (MS)
patients compared to healthy individuals and correlate them
with the severity of MS.
Materials and methods: Sixty participants, including 30
patients with MS and 30 healthy controls were studied. The
expression of PIAS1 and PIAS2 genes in peripheral blood sam-
ples of all participants was measured by real-time PCR. The
severity of MS was evaluated using the Expanded Disability
Status Scale (EDSS). Finally, we evaluated the correlation
between the expression of PIAS1 and PIAS2 genes with disease
severity.
Results: The expression of PIAS1 gene was increased in patients
with MS compared to healthy subjects (P value<.001). Also,
there was a significant correlation between the expression of
PIAS1 and PIAS2 genes with disease severity according to EDSS.
Conclusion: Our study suggests the expression of PIAS1 and
PIAS2 genes as a prognostic and diagnostic marker in MS disease.
KEYWORDS
Multiple sclerosis; PIAS1;
PIAS2; EDSS
Introduction
Multiple sclerosis (MS), a chronic autoimmune demyelinating disease of central
nervous system,[1] is mediated by autoreactive T cells[2] and leads to progressive
neurological disability.[3] It is estimated that about 2.5 million people worldwide
are diagnosed with MS, mainly young adults at the age between 20 and 40.[4] The
etiology of MS is yet unknown; however, a combination of immunological as well
as environmental factors such as vitamin D deficiency, smoking,[5] increase in
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cytomegalovirus, positivity of anti-CMV IgG and IgM antibodies,[6] decreased
Helicobacter pylori,[7] imbalance of inflammatory and anti-inflammatory factors,[8]
and genetic factors[9] are thought to be cause or contribute toMS.The classification
ofMS based on the severity of clinical symptoms includes: relapsing-remittingMS
(RRMS), secondary progressive MS (SPMS), progressive relapsing MS (PRMS),
and primary progressive MS (PPMS).[8] Depending on the brain regions attacked
by the immune system, the patients suffer from a variety of symptoms including
muscle weakness, paresthesia, ataxia, and visual disturbances.[4] Successful thera-
pies target the immune system indicating such system plays an important role in
the disease activity.
Different combinations of the Janus kinas/Signal Transducer and Activator of
Transcription (JAK/STAT) factors, utilized by over 70 cytokines as well as growth
factors,[10] initiate and orchestrate innate and adaptive immune responses.[9] The
regulation of such pathway seems to be critical; and in this regard, the Protein
Inhibitor of Activated STAT (PIAS) proteins contribute in endogenous negative
regulation of JAK/STAT pathway.[11] Actually, dysregulation of JAK/STAT path-
way has pathologically been implicated in some autoimmune diseases such
as MS.[3]
PIAS family consists of PIAS1, PIAS2 (also known as PIASx), PIAS3, and
PIAS4 (also known as PIASy).[12,13] PIAS3 and PIAS2 interact with STAT3 and
STAT4, respectively; while PIAS1 and PIASy interact with STAT1.[13] It has
been proposed that PIASs regulate the function of over 60 proteins through
various molecular mechanisms[14–16] including blocking the DNA binding
activity of transcription factors, recruiting transcriptional co-receptors or coac-
tivators, promoting protein somuylation, and sequestrating transcription fac-
tors to certain subnuclear structures where co-receptor complexes are
enriched.[14,15] This family also acts as potential regulators of cell proliferation,
inflammatory responses,[17,18] and tumor development.[19] The PIAS family
expression is known to be related to many inflammatory and autoimmune
diseases such as CNS inflammation,[20–22] several oncogene conditions,[23] type
2 diabetes mellitus,[24] and viral infections.[25]
Considering the effects of PIAS protein family in inflammatory conditions,
we proposed the probable relation of gene expression of PIAS1 and PIAS2 to
the autoimmune disease of MS and its severity. Such investigation may reveal
a prognostic role of PIAS1 and PIAS2 in MS and may also suggest new
therapeutic clues.
Methods and materials
Study subjects
This case–control study was performed on 30 patients with MS and 30
healthy volunteers in the Neurology Clinic of Shahid Beheshti Hospital in
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Kashan city, Iran. The inclusion criteria were MS patients with ages between
20 and 60, course of disease (RRMS, PPMS, SPMS, and PRMS) identified
according to McDonald criteria.[26] All patients were treated with IFN-β. Any
other chronic inflammatory/autoimmune diseases, clinical relapse, and glu-
cocorticoid therapy during the past 1 month were considered as exclusion
criteria. Healthy volunteers had no any history of chronic inflammatory and
autoimmune diseases. In addition, healthy participants were matched to the
patients for age and gender. The protocol was approved by the ethics
committee of Kashan University of Medical Science. Written informed con-
sent was obtained from all participants.
Clinical assessment
The severity of MS was evaluated using the Expanded Disability Status Scale
(EDSS), a clinician-administered assessment scale evaluating the functional
systems of the central nervous system. Today, EDSS is used to describe disease
progression in patients with MS and to assess the effectiveness of therapeutic
interventions in clinical trials.[8,27] It consists of ordinal rating system ranging
from 0 (normal neurological status) to 10 (death due to MS) in 0.5 increments
interval.[28] Patients were divided into two groups of mild and severe according
to their EDSS score. Patients with the score of 0.5–4.5 were placed in mild
group and those with the EDSS score of 5–9.5 were placed in severe group.
Patients in remission phase were enrolled in the study.
Laboratory procedures
Peripheral venous blood samples were collected from all participants. Fresh
peripheral blood mononuclear cells were separated from 2 ml of anticoagulated
blood by Ficoll–Hypaque (Lymphodex, Inno-Train, Germany) density gradient
centrifugation. Total RNA was extracted from peripheral blood mononuclear
cells using High Pure RNA Isolation Kit (Cat No: 11828665001, Roche Applied
Science, Germany), and cDNA was synthesized from the extracted RNA using
Transcriptor First Strand cDNA Synthesis Kit (Cat No: 04897030001, Roche
Applied Science, Germany). The amounts of PIAS1 and PIAS2 gene expression
were measured through Taqman primer probe Comparative CT method using
ABI 7300 Real-Time PCR system. β-Actin housekeeping gene was used as
endogenous control.
Statistical analysis
The statistical indices of the PIAS1 and PIAS2 gene expression were analyzed
by independent t and chi-square tests. Using Pearson’s correlation coeffi-
cient, we calculated the correlations between variables. All analyses were
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performed using the SPSS 16 software. Data were expressed as mean ± stan-
dard deviation (SD).
Results
The expression of PIAS1 gene was 9.13 ± 1.96 and 6.77 ± 1.99 in MS patients
and healthy controls, respectively. The expression of PIAS1 gene was sig-
nificantly higher in MS patients than in healthy subjects (P < .001). However,
there was no significant difference in the expression of PIAS2 gene between
two groups (P = .39) (Table 1).
We found a significant correlation between the gene expression of PIAS1
with EDSS score (R = 0.65, P < .001). We also found a significant correlation
between the expression of PIAS2 gene with EDSS score (R = 0.58, P < .001).
The correlation between PIAS1 and PIAS2 gene expression was 0.32
(P = .012) (Table 2).
The expression of PIAS1 gene was significantly higher in severe forms
(10.3 ± 1.25) of MS than that in mild forms (8.55 ± 2.01) (P = .018). There
was also a significant increase in the gene expression of PIAS2 according to
EDSS score. The gene expression of PIAS2 was 7.55 ± 1.39 in mild forms of
MS and 8.7 ± 1.25 in severe forms (P = .036) (Table 3).
Using receiver operating characteristic (ROC) curve and Area under Curve
(AUC), we determined the sensitivity and specificity of both PIAS1 and
PIAS2 gene expression as diagnostic markers of MS severity. In the best
cutoff point of PIAS1 gene expression = 7.5, sensitivity and specificity were
80% and 63.3%, respectively; and AUC was determined as 0.802. Considering
Table 1. Basic and clinical characteristic of MS patients and healthy subjects.
Variants MS patients (n = 30) Healthy controls (n = 30) P value
Age (years) 38.11 ± 13.88 29.92 ± 9.52 0.019
Gender (male/female) (5/25) (9/21) 0.222
Disease duration (years) 6.62 ± 4.18 – –
Type of disease RRMS 23 (76.7%) – –
PPMS 0 (0%) –
SPMS 5 (16.7%) –
PRMS 2 (6.7%) –
Type of treatment No drug 2 (7.1%) – –
Cinovex 20 (71.4%) –
Rebief 5 (17.9%) –
Others 1 (3.6%) –
Family history Positive 4 (13.3%) – –
Negative 26 (86.7%) –
Number of relapses 4.4 ± 4.1 – –
Treatment duration (years) 3.58 ± 3.1 – –
EDSS Mild (0.5–4.5) 20 (66.6%) – –
Severe (5–9.5) 10 (33.3%) – –
PIAS1 9.13 ± 1.96 6.77 ± 1.99 < 0.001
PIAS2 7.93 ± 1.43 7.53 ± 2.09 0.392
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the optimal cutoff point of PIAS2 gene expression = 6.5, sensitivity was 80%
and specificity was 33.3%, and AUC was determined as 0.554 (Table 4)
(Figure1).
Discussion
The present study aimed to evaluate the gene expression of PIAS1 and PIAS2 in
MS patients. Rare studies evaluated PIASs in patients with MS. In a study by
Catherine O’Doherty et al.,[20] a significant relevancy between the gene expres-
sion of PIAS1 and MS as well as responding to IFN-B treatment has been
shown. Multi-allelic combinations analysis determined a JAK2-IL10RB-GBP1-
PIAS1 combination was most significant. Evaluating the potential underlying
biallelic patterns showed JAK2–IL10RB as the core element. However, the
triplet including quartet with an additional PIAS1 allele or GBP1 allele demon-
strated to be more influential.[20] By evaluating RRMS peripheral blood mono-
nuclear cells in the active and stable phases and its differences, a specific
genomic signature for RRMS was determined, which PIAS-1were determined
is related to the active phase of RRMS.[29] However, in contrast to the results of
these studies, there was no significant change in gene expression of PIAS genes
between autism spectrum disorder patients and healthy subjects.[30] The
Table 2. Pearson‘s correlation coefficient between the expression of PIAS1 and PIAS2 genes with
other variables in multiple sclerosis (MS) patients.
PIAS1 PIAS2
Correlation coefficient P value Correlation coefficient P value
PIAS1 1 – 0.322 0.012
PIAS2 0.322 0.012 1 –
EDSS 0.656 < 0.001 0.588 0.001
Number of relapses 0.374 0.042 0.314 0.091
Treatment duration 0.294 0.121 0.225 0.241
Duration of disease 0.308 0.098 0.112 0.557
Age 0.346 0.012 −0.048 0.733
Table 3. PIAS1 and PIAS2 gene expression according to MS severity.
Variant EDSS group Number Mean ± SD P value
PIAS1 Mild (0.5–4.5) 20 8.55 ± 2.012 0.018
Severe (5–9.5) 10 10.30 ± 1.252
PIAS2 Mild (0.5–4.5) 20 7.55 ± 1.395 0.036
Severe (5–9.5) 10 8.7 ± 1.252
Table 4. Sensitivity and specificity of PIAS1 and PIAS2 gene expression in ROC curve.
Inflammatory markers Optimal cutoff point Sensitivity Specificity LR+ LR− AUC
PIAS1 7.5 80% 63.3% 2.17 3.16 0.802
PIAS2 6.5 80% 33.3% 1.19 1.665 0.554
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differences in diseases and its pathophysiology might explain the discrepancies
among the results of studies.
Mechanistically, Members of PIAS family have been shown to interact with
various STATs.[14] PIAS3 and PIAS2 interact with STAT3 and STAT4, respec-
tively; and PIAS1 and PIASy interact with STAT1. PIAS1 and PIAS3 exert their
negative regulation by blocking the DNA binding of STAT1 and STAT3,
respectively.[13,15] On the other hand, PIAS2 and PIASy repress the transcriptional
activity of STAT1 and STAT4 by recruiting co-repressormolecules such as histone
deacetylases.[13] Particularly, PIAS1 is a key regulator of the inflammation cascade
of innate immunity.[24] Such role of PIAS1 has been suggested in the control of
autoimmune conditions such as insulin sensitivity in type 2 diabetes,[24] essential
thrombocytopenia,[31] and primary hyperaldosteronism.[32] PIAS1 overexpression
has also been implicated in the regulation of several oncogenic conditions[23] such
as multiple myeloma,[12] breast,[33] prostate,[34] colon,[19] and lung cancer[23] as
well as infections of HIV[35] and HSV1.[36,37] In neurogenic tissues, PIAS1 expres-
sion is linked to neuronal plasticity as well as neuro-inflammation; and from this
point of view, its expression may be associated with Huntington.[22]
In line with the results of other study,[29] our data showed an increased gene
expression of PIAS1 in MS patients that was correlated to disease severity
according to EDSS score. Considering the role of PIAS1 as an inhibitory factor
of JAK-STAT pathway, we may conclude that the overexpression of PIAS1 in
MS patients acts as a protective mechanism to decrease the disease severity.
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Figure 1. Sensitivity and specificity of PIAS1 and PIAS2 gene expression.
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Although, such mechanism would not be adequate to compensate the disease
development, it may suggest a possible therapeutic clue in autoimmune condi-
tion of MS. Such association has also been shown in the case of other inflam-
matory cytokine inhibitors like SOCS1 and SOCS3.[38,39] The relationship
described above between PIAS1 and clinical conditions has also been shown
in the case of PIAS2. For example, PIAS2 is overexpressed in several malignan-
cies such as malignant melanoma[40] as well as thyroid cancer[41] and viral
infections such as HBV and HCV.[25,42] PIAS2 also plays some roles in neuronal
system. A study suggested the novel role of PIAS2 somuylation in brain devel-
opment and plasticity.[43] From this point of view, PIAS2 alterations may
contribute in some brain-related diseases such as schizophrenia.[21] In a recent
study, Vavougios et al. showed a significant relation between PIAS2 gene
expression and MS disease.[44] Unlike the latter study,[44] we found no signifi-
cant relation between gene expression of PIAS2 and MS disease. However, the
gene expression of PIAS2 was associated to disease severity. According to EDSS
score, PIAS2 gene expression was significantly higher in severe forms ofMS than
in mild forms. Our study showed a significant correlation between the expres-
sion of both PIAS1 and PIAS2 genes with disease severity according to EDSS
score. This finding suggests PIAS1 and PIAS2 as predictors of severe forms of
MS which is independent of sex, treatment duration, and the duration of the
disease. We also demonstrated that the specificity of PIAS1 gene expression was
higher than PIAS2 gene expression in the diagnosis of MS. It may reveal the
potential role of PIAS1 as a new diagnostic factor for MS disease.
The limitation of our study was that we did not monitor the gene expression of
PIAS1 and PIAS2 longitudinally. This limitation allowed just a cross-sectional
analysis of their changes of only limited robustness. Other factors except for PIAS1
and PIAS2, such as other PIAS genes may affect the MS severity which should be
determined in future studies. Unfortunately, due to funding limitations, we did not
assess the gene expression of other PIAS genes in the patients withMS. Moreover,
further studies are needed to confirm those findings with larger sample size.
Conclusion
Our findings show the elevation of expression of PIAS1 gene in patients with
MS compared to healthy controls. We demonstrated that the PIAS1 and
PIAS2 gene expression is correlated to disease severity according to EDSS.
These findings may reveal a new diagnostic approach to MS severity and also
suggests new therapeutic approaches to this disease.
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